Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SimpliciTB: BPaMZ Regimen in Drug-Sensitive and Drug-Resistant Pulmonary Tuberculosis
NCT03338621Phase 3Completed
- Sponsor
- TB Alliance
- Start
- Jul 2018
- Primary completion
- Jul 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of bedaquiline, pretomanid, moxifloxacin, pyrazinamide in pulmonary tuberculosis (TB), multidrug-resistant tuberculosis (MDR-TB), sponsored by TB Alliance. Started Jul 2018; status: completed.
02
Drugs
bedaquilinepretomanidmoxifloxacinpyrazinamide
03
Conditions
pulmonary tuberculosis (TB)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03338621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338621.